Addressing Care Coordination and Financial Toxicity in HER2+ Breast Cancer

Gaps in care coordination remain a challenge for HER2-positive breast cancer patients, particularly in communication between oncologists, pharmacists, and payers. Rapidly evolving HER2-targeted therapies can outpace guideline updates from organizations like NCCN and ASCO, leaving clinicians navigating complex treatment decisions with limited consensus. Financial toxicity is a growing concern, encompassing the economic burden of treatment costs, copayments, and ancillary expenses that can impact adherence and quality of life. Addressing these issues requires proactive strategies, including early engagement of financial counseling, assistance programs, and transparent discussions about treatment costs. System-level interventions—such as aligning coverage policies with emerging evidence and supporting multidisciplinary care teams—can help reduce both clinical and financial barriers. Optimizing coordination and mitigating financial strain are essential to ensure equitable access and maximize outcomes for patient